Trial Profile
A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE-206)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Acimtamig (Primary) ; Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Proof of concept
- Acronyms KEYNOTE- 206
- 19 Nov 2020 Results presented in an Affimed Therapeutics media release
- 30 Jul 2020 Results of safety and preliminary efficacy published in the Blood
- 24 Jun 2019 Results presented in an Affimed Therapeutics media release.